Neuropolybin: A new antiseizure peptide obtained from wasp venom.


Journal

Biochemical pharmacology
ISSN: 1873-2968
Titre abrégé: Biochem Pharmacol
Pays: England
ID NLM: 0101032

Informations de publication

Date de publication:
11 2020
Historique:
received: 31 03 2020
revised: 18 06 2020
accepted: 19 06 2020
pubmed: 27 6 2020
medline: 5 1 2021
entrez: 27 6 2020
Statut: ppublish

Résumé

Epilepsy accounts for one of the most serious neurological disorders, and its treatment remains a challenge, due to high cost and harmful side effects. Bioactive molecules extracted from arthropod venoms are considered a promising therapy since these compounds are known for their highly selective and potent profiles. The purpose of this study was to identify and characterize the potential antiseizure effect of the peptide Ppnp7, extracted from the venom of the social wasp Polybia paulista, and also the effect of the bioinspired peptide, named Neuropolybin, in the same parameters. Additionally, we also evaluated the electroencephalographic (EEG) profile in the PTZ-induced acute seizures in animals treated with Neuropolybin, and potential adverse effects of both peptides in general spontaneous activity (Open Field analysis). Interestingly, Ppnp7 and Neuropolybin showed a noteworthy antiseizure effect in rats and mice, respectively. Curves of protection against the maximum seizure were obtained for both peptides, and EEG records demonstrated that Neuropolybin protected 80% of animals from tonic-clonic seizures when applied with a dose of 3 nmol (an approximate Ppnp7 ED

Identifiants

pubmed: 32589997
pii: S0006-2952(20)30355-5
doi: 10.1016/j.bcp.2020.114119
pii:
doi:

Substances chimiques

Anticonvulsants 0
Peptides 0
Wasp Venoms 0
Pentylenetetrazole WM5Z385K7T

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

114119

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Juliana de Castro E Silva (J)

Neuropharmacology Laboratory, Institute of Biological Sciences, Department of Physiological Sciences, University of Brasília, Distrito Federal, DF, Brazil.

Lucianna Lopes do Couto (L)

Neuropharmacology Laboratory, Institute of Biological Sciences, Department of Physiological Sciences, University of Brasília, Distrito Federal, DF, Brazil.

Henrique de Oliveira Amaral (H)

Neuropharmacology Laboratory, Institute of Biological Sciences, Department of Physiological Sciences, University of Brasília, Distrito Federal, DF, Brazil.

Flávia Maria Medeiros Gomes (F)

Neuropharmacology Laboratory, Institute of Biological Sciences, Department of Physiological Sciences, University of Brasília, Distrito Federal, DF, Brazil.

Gabriel Avohay Alves Campos (G)

Neuropharmacology Laboratory, Institute of Biological Sciences, Department of Physiological Sciences, University of Brasília, Distrito Federal, DF, Brazil.

Luciano Paulino Silva (L)

Mass Spectrometry Laboratory, EMBRAPA Genetic Resources and Biotechnology, Distrito Federal, DF, Brazil.

Márcia Renata Mortari (M)

Neuropharmacology Laboratory, Institute of Biological Sciences, Department of Physiological Sciences, University of Brasília, Distrito Federal, DF, Brazil. Electronic address: mmortari@unb.br.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH